The future of atrial fibrillation therapy

Journal of Cardiovascular Electrophysiology

Volumn 17, Issue SUPPL. 2, 2006, Pages

  Dorian, Paul ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Ablation; Antiarrhythmic drugs; Atrial fibrillation; Pharmacotherapy

Indexed keywords

AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRONEDARONE; ENALAPRIL; FISH OIL; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; LOSARTAN; POLYUNSATURATED FATTY ACID; PREDNISONE; SOTALOL; STEROID; TRANDOLAPRIL; VERAPAMIL;

ALCOHOL CONSUMPTION; ANTIINFLAMMATORY ACTIVITY; BRADYCARDIA; CARDIOVERSION; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY; ELECTROPHYSIOLOGY; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE FIBROSIS; HEART PACING; HEART RATE; HUMAN; MYOCARDITIS; OBESITY; PRIORITY JOURNAL; QUALITY OF LIFE; RADIOFREQUENCY ABLATION; RISK FACTOR; SINUS NODE; SINUS RHYTHM; SLEEP APNEA SYNDROME; STROKE; SUPRAVENTRICULAR TACHYCARDIA; UNSPECIFIED SIDE EFFECT;

ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CATHETER ABLATION; COMBINED MODALITY THERAPY; FORECASTING; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES;

EID: 33746684300     PISSN: 10453873     EISSN: 15408167     Source Type: Journal    
DOI: 10.1111/j.1540-8167.2006.00582.x     Document Type: Conference Paper

References (35)

1. Wattigney WA, Mensah GA, Croft JB: Increased atrial fibrillation mortality: United States, 1980-1998. Am J Epidemiol 2002;155:819-826.
2. Stewart S, Hart CL, Hole DJ, McMurray JJ: A population-based study of the long-term risks associated with atrial fibrillation: A 20-year follow-up of the Renfrew-Paisley study. Am J Med 2002;113:354-359.
3. Wolf PA, Abbott RD, Kannel WB: Atrial fibrillation: A major contributor to stroke in the elderly. The Framingham study. Arch Intern Med 1987;147:1561-1564.
4. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD: Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-1833.
5. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, Said SA, Darmanata JI, Timmermans AJ, Tijssen JG, Crijns HJ: Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002;347:1834-1840.
6. Hohnloser SH, Kuck KH, Lilienthal J: Rhythm or rate control in atrial fibrillation - Pharmacological Intervention in Atrial Fibrillation (PIAF): A randomised trial. Lancet 2000;356:1789-1794.
7. Carlsson J, Neuzner J, Rosenberg YD: Therapy of atrial fibrillation: Rhythm control versus rate control. Pacing Clin Electrophysiol 2000;23:891-903.
8. Opolski G, Torbicki A, Kosior DA, Szulc M, Wozakowska-Kaplon B, Kolodziej P, Achremczyk P: Investigators of the Polish How to Treat Chronic Atrial Fibrillation Study. Rate control vs. rhythm control in patients with nonvalvular persistent atrial fibrillation. The results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study. Chest 2004;126:476-486.
9. Camm AJ, Savelieva I: Advances in antiarrhythmic drug treatment of atrial fibrillation: Where do we stand now? Heart Rhythm 2004;1:244-246.
10. Furberg CD, Manolio TA, Psaty BM, Bild DE, Borhani NO, Newman A, Tabatznik B, Rautaharju PM: Major electrocardiographic abnormalities in persons aged 65 years and older (the Cardiovascular Health Study). Am J Cardiol 1992;69:1329-1335.
11. Kannel WB, Wolf PA, Benjamin EJ, Levy D: Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: A population-based estimates. Am J Cardiol 1998;82:2N-9N.
12. Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautahaju PM: Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol 1994;74:236-241.
13. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA: Atrial fibrillation begets atrial fibrillation: A study in awake chronically instrumented goats. Circulation 1995;92:1954-1968.
14. Singh BN, Singh SN, Reda DJ, Tang XC, Lopez B, Harris CL, Fletcher RD, Sharma SC, Atwood JE, Jacobson AK, Lewis HD Jr, Raisch DW, Ezekowitz MD: Sotalol Amiodarone Atrial Fibrillation Efficacy Trial (SAFE-T) Investigators. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 2005;352:1861-1872.
15. Dorian P, Jung W, Newman D, Paquette M, Wood K, Ayers GM, Camm J, Akhtar M, Luderitz B: The impairment of health-related quality of life in patients with intermittent atrial fibrillation: Implications for investigational therapy. J Am Coll Cardiol 2000;36:1303-1309.
16. Hohnloser SH: EURIDIS and ADONIS maintenance of sinus rhythm with dronedarone in patients with atrial fibrillation or flutter. Hot Line II: Acute coronary syndromes/medical treatment II. Presented at the European Society of Cardiology Congress 2004; August 28-September 1, 2004; Munich, Germany.
17. Camm AJ, Savelieva I: Advances in antiarrhythmic drug treatment of atiral fibrillation: Where do we stand now? Heart Rhythm 2004;1:244-246.
18. de Denus S, Sanoski CA, Carlsson J, Opolski G, Spinler SA: Rate versus rhythm control in patients with atrial fibrillation. A meta-analysis. Arch Intern Med 2005;165:258-262.
19. Pedersen OD, Bagger H, Kober L, Torp-Pedersen C: Trandolopril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999;100:376-380.
20. Vermes E, Tardif JC, Bourassa MG, Racine N, Levesque S, White M, Guerra PG, Ducharme A: Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction. Insight from the Left Ventricular Dysfunction (SOLVD) Trials. Circulation 2003;107:2926-2931.
21. Murray KT, Rottman JN, Arbogast PG, Shemanski L, Primm RK, Campbell WB, Solomon AJ, Olgin JE, Wilson MJ, Dimarco JP, Beckman KJ, Dennish G, Naccarelli GV, Ray WA, the AFFIRM Investigators: Inhibition of angiotensin II signaling and recurrence of atrial fibrillation in AFFIRM. Heart Rhythm 2004;1:669-675.
22. Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlof B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Devereux RB: Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol. J Am Coll Cardiol 2005;45:712-719.
23. Madrid AH, Bueno MG, Rebollo JM, Marin I, Pena G, Bernal E, Rodriguez A, Cano L, Cano JM, Cabeza P, Moro C: Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation. A prospective and randomized study. Circulation 2002;106:331-336.
24. Mitchell LB, Powell JL, Gillis AM, Kehl V, Hallstrom AP: AVID Investigators. Are lipid-lowering drugs also antiarrhythmic drugs? An analysis of the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial. J Am Coll Cardiol 2003;42:81-87.
25. Siu C-W, Lau C-P, Tse H-F: Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am J Cardiol 2003;92:1343-1345.
26. Young-Xu Y, Jabbour S, Goldberg R, Blatt CM, Graboys T, Bilchik B, Ravid S: Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol 2003;92:1379-1383.
27. Lefer DJ: Statins as potent anti-inflammatory drugs. Circulation 2002;106:2041-2042.
28. Chung MK, Martin DO, Sprecher D, Wazni O, Kanderian A, Carnes CA, Bauer JA, Tchou PJ, Niebauer MJ, Natale A, Van Wagoner DR: C-reactive protein elevation in patients with atrial arrhythmias. Circulation 2001;104:2886-2891.
29. Dernellis J, Panaretou M: Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. Eur Heart J 2004;25:1100-1107.
30. Mozaffarian D, Psaty BM, Rimm EB, Lemaitre RN, Burke GL, Lyles MF, Lefkowitz D, Siscovick DS: Fish intake and risk of incident atrial fibrillation. Circulation 2004;110:368-373.
31. Calo L, Bianconi L, Colivicchi F, Lamberti F, Loricchio ML, de Ruvo E, Meo A, Pandozi C, Staibano M, Santini M: N-3 fatty acids for the prevention of atrial fibrillation after coronary bypass surgery. J Am Coll Cardiol 2005;45:1723-1728.
32. Gami AS, Friedman PA, Chung MK, Caples SM, Somers VK: Therapy Insight: Interactions between atrial fibrillation and obstructive sleep apnea. Nat Clin Pract Cardiovasc Med 2005;2:145-149.
33. Cappato R, Calkins H, Chen SA, Davies W, Iesaka Y, Kalman J, Kim YH, Klein G, Packer D, Skanes A: Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circulation 2005;111:1100-1105.
34. Connolly S: Late breaking trials, AHA Scientific Sessions, November 14, 2006. Dallas, Texas.
35. Wallentin LC, Ezekowitz M, Simmers TA, Pedersen KE, Stangier J, Nehmiz G, Reilly P: on behalf of PETRO investigators. Safety and efficacy of a new oral direct thrombin inhibitor Dabigatran in atrial fibrillation - A dose finding trial with comparison to Warfarin [abstract]. Eur Heart J 2005;26(Suppl):482- 483.